Conference abstract · 27 Sep 2018
Review articlePublished 25 Sep 2011
Japanese Encephalitis Vaccines
Department of Pediatrics, University of Maryland, Baltimore MD, USA; NIAID Integrated Research Facility, Ft. Detrick, Frederick MD, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Japanese encephalitis (JE) is a significant human health concern in Asia, Indonesia and parts of Australia with more than 3 billion people potentially at risk of infection with Japanese encephalitis virus (JEV), the causative agent of JE. Given the risk to human health and the theoretical potential for JEV use as a bioweapon, the development of safe and effective vaccines to prevent JEV infection is vital for preserving human health. The development of vaccines for JE began in the 1940s with formalin-inactivated mouse brain-derived vaccines. These vaccines have been shown to induce a protective immune response and to be very effective. Mouse brain-derived vaccines were still in use until May 2011 when the last lots of the BIKEN® JE-VAX® expired. Development of modern JE vaccines utilizes cell culturederived viruses and improvements in manufacturing processes as well as removal of potential allergens or toxins have significantly improved vaccine safety. China has developed a live-attenuated vaccine that has proven to induce protective immunity following a single inoculation. In addition, a chimeric vaccine virus incorporating the prM and E structural proteins derived from the live-attenuated JE vaccine into the live-attenuated yellow fever 17D vaccine virus backbone is currently in clinical trials. In this article, we provide a summary of JE vaccine development and on-going clinical trials. We also discuss the potential risk of JEV as a bioweapon with a focus on virus sustainability if used as a weapon.
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 25 Oct 2019
Single dose of live attenuated SA 14-14-2 Japanese Encephalitis vaccine provides long-term protection against Japanese Encephalitis: A case-control study in Nepalese children
Conference abstract · 27 Jul 2015
Advax-adjuvanted killed Japanese encephalitis virus (JEV) vaccine is safe in pregnant mares and in foals and induces robust immunological memory.
Conference abstract
Treg cells regulates antibody response to Japanese encephalitis vaccination
Conference abstract
An immunoinformatics analysis and structure based modeling of potential HLA class II allele binding T cell epitopes for vaccine design of Japanese Encephalitis Virus
More from this journal
The newest in Journal of Bioterrorism & Biodefense.
Editorial · 10 Dec 2025
Advanced Biodefense: Detection, Prevention, Preparednes
Case report · 10 Dec 2025
CRISPR: Enhancing Plant Resistance for Sustainability
Editorial · 10 Dec 2025
Adaptive Global Biodefense Against Future Threats
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioterrorism & Biodefense
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Monica A. McArthur”
- BylineArticles whose byline prints “Michael R. Holbrook”
